Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
A fresh licensing deal tidies up years of work between the two companies.
And that could affect the drug's third-line accelerated approval.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
